Hanna Bjorkelund
Overview
Explore the profile of Hanna Bjorkelund including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
260
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Encarnacao J, Napolitano V, Opassi G, Danielson U, Dubin G, Popowicz G, et al.
FEBS Lett
. 2020 May;
594(15):2406-2420.
PMID: 32473599
The interaction between the Shiga toxin B-subunit (STxB) and its globotriaosylceramide receptor (Gb3) has a high potential for being exploited for targeted cancer therapy. The primary goal of this study...
2.
Encarnacao J, Schulte T, Achour A, Bjorkelund H, Andersson K
Appl Microbiol Biotechnol
. 2018 Mar;
102(9):4193-4201.
PMID: 29550990
Time-resolved analysis assays of receptor-ligand interactions are fundamental in basic research and drug discovery. Adequate methods are well developed for the analysis of recombinant proteins such as antibody-antigen interactions. However,...
3.
Bondza S, Bjorkelund H, Nestor M, Andersson K, Buijs J
Anal Chem
. 2017 Nov;
89(24):13212-13218.
PMID: 29160688
Cellular receptor activity is often controlled through complex mechanisms involving interactions with multiple molecules, which can be soluble ligands and/or other cell surface molecules. In this study, we combine a...
4.
Hillerdal V, Boura V, Bjorkelund H, Andersson K, Essand M
BMC Immunol
. 2016 Jul;
17(1):23.
PMID: 27411667
Background: Adoptive transfer of genetically engineered autologous T-cells is becoming a successful therapy for cancer. The avidity of the engineered T-cells is of crucial importance for therapy success. We have...
5.
Bondza S, Stenberg J, Nestor M, Andersson K, Bjorkelund H
Mol Pharm
. 2014 Sep;
11(11):4154-63.
PMID: 25252166
Antibody-drug conjugates (ADC) have shown promising effects in cancer therapy by combining the target specificity of an antibody with the toxicity of a chemotherapeutic drug. As the number of therapeutic...
6.
Wang E, Bjorkelund H, Mihaylova D, Hagemann U, Karlsson J, Malmqvist M, et al.
Nucl Med Commun
. 2014 Apr;
35(7):767-76.
PMID: 24709981
Background: The number of radiolabeled monoclonal antibodies (mAbs) used for medical imaging and cancer therapy is increasing. The required chemical modification for attaching a radioactive label and all associated treatment...
7.
Koch S, van Meeteren L, Morin E, Testini C, Westrom S, Bjorkelund H, et al.
Dev Cell
. 2014 Mar;
28(6):633-46.
PMID: 24656741
Neuropilin 1 (NRP1) modulates angiogenesis by binding vascular endothelial growth factor (VEGF) and its receptor, VEGFR2. We examined the consequences when VEGFR2 and NRP1 were expressed on the same cell...
8.
Bjorkelund H, Gedda L, Malmqvist M, Andersson K
Mol Clin Oncol
. 2014 Mar;
1(2):343-352.
PMID: 24649173
Overexpression and aberrant activity of the epidermal growth factor (EGF) have been observed in various cancer types, rendering it an important target in oncology research. The interaction between EGF and...
9.
Borzecka K, Plociennikowska A, Bjorkelund H, Sobota A, Kwiatkowska K
Mediators Inflamm
. 2014 Feb;
2013:824919.
PMID: 24489448
Activation of macrophages with lipopolysaccharide (LPS) involves a sequential engagement of serum LPS-binding protein (LBP), plasma membrane CD14, and TLR4/MD-2 signaling complex. We analyzed participation of CD14 in TNF-α production...
10.
Dubois L, Andersson K, Asplund A, Bjorkelund H
BMC Res Notes
. 2013 Dec;
6:542.
PMID: 24350799
Background: Immunohistochemistry (IHC) is a well-established method for the analysis of protein expression in tissue specimens and constitutes one of the most common methods performed in pathology laboratories worldwide. However,...